A new rapid blood culture test system for sepsis can reduce identification to 12 hours, from the two-to-three days of standard-of- care culture and antibiotic susceptibility testing.
This is the largest study to evaluate the clinical impact of rapid blood culture diagnostics in the management of patients with gram-negative bacilli bloodstream infections. The results demonstrate that providing rapid, accurate drug susceptibility information to physicians could improve the care of patients with sepsis, a potentially life-threatening condition caused by the body’s response to an infection.
Conventional testing can take two to three days before the bacteria in the blood and its drug resistance are fully identified. Utilising the rapid testing method gave medical teams final results in about 12 hours.
According to Dr Ritu Banerjee, associate professor of paediatrics at Monroe Carell Jr Children’s Hospital at Vanderbilt University Medical Centre, time is of the essence. “Patients are placed on a standard course of antibiotics when they initially present with possible sepsis,” said Banerjee, the principal investigator of the RAPIDS-GN trial. “These antibiotics may be ineffective, or conversely, too broad-spectrum. Conventional culture and susceptibility testing methods take days for results to identify the bacteria and drug resistance.
“Instead of waiting days for results, we can now get them in hours.”
Banerjee and her colleagues sought a way to shorten the wait time until the appropriate medication could be started to treat the infection.
RAPIDS-GN, is the first multicentre, prospective, randomised controlled trial to compare the outcomes of patients with gram-negative bloodstream infections who had blood culture testing with standard-of- care culture and antibiotic susceptibility testing versus rapid organism identification and phenotype antibiotic susceptibility testing.
The study looked at the outcomes of 448 patients – 226 received conventional care while 222 were randomised to the new testing method.
The rapid organism identification and phenotype antibiotic susceptibility testing used the Accelerate Pheno System. The study, sponsored by the Antibacterial Resistance Leadership Group, which consists of more than 50 leading experts working together to combat the antibacterial resistance crisis and improve patient care, was conducted at the Mayo Clinic and University of California Los Angeles. Banerjee led the study remotely.
“The time to results was significantly shorter,” said Banerjee. “The median time to the first antibiotic change was 24 hours faster in the rapid testing arm compared to the control arm. We can now tailor the antibiotics more quickly and place patients on pathogen-directed therapy rather than broad-spectrum, empiric therapy.
“This was a very positive result. It was proof that faster actionable results led to timelier, targeted antibiotic therapy. The hope is that this, in turn, leads to better patient outcomes, less unnecessary broad-spectrum antibiotic use, and less emergence of drug resistant organisms.”
Banerjee also hopes the study results prompt more diagnostic companies to continue the development of platforms that will enable more rapid bacterial identification and resistance detection.
“One of the challenges is the cost of the testing, because rapid testing methods are more expensive than conventional methods,” she said. “The overarching goal is to improve outcomes for patients with sepsis.”
The study as reported on at IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA).
Not yet available online